Community Research and Development Information Service - CORDIS

  • European Commission
  • CORDIS
  • Publications
  • Final Report - NORMOLIFE (Development of new therapeutic substances and strategies for treatment of pain in patients with advanced stages of cancer)
FP6

Final Report - NORMOLIFE (Development of new therapeutic substances and strategies for treatment of pain in patients with advanced stages of cancer)

Project ID: 37733
Funded under: FP6-LIFESCIHEALTH

Abstract

Prolonging the life expectations of patients with progressive cancer could be done by modern medicine. However, progressive pain that is associated with progression of disease is the major factor that destructs last moment of life. Severe and progressive and uncontrolled pain is a major reason of requesting euthanasia. The applications of oral (morphine) pills or transdermal patches with lipophylic analgesic drugs are the most common treatments of cancer pain. These compounds penetrating into central nervous system produce side effects (respiratory depression, constipation, tolerance, sedation etc) to such extend that pain treatment is reduced by the doctor or refused by the patients.

Therefore, as expressed in the project's final report: the objectives of this project have been focused on development of new multi-target antinociceptive compounds that may interact with peripheral receptors expressed in inflamed and / or pathologically modified tissues and suppress generation and transmission of nociceptive signals from the periphery to CNS. As further outlined, the project involved, in general, complementary scientific objectives: chemistry, in vitro biopharmacology and in vivo pharmacology that were accomplished by multidisciplinary integrated teams.

Download application/pdf (536563)

Related information

Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top